Item 8.01 Other Events.

On January 9, 2020, VBI Vaccines Inc. (the "Company") issued a press release announcing that the second pivotal Phase 3 study of Sci-B-Vac®, the Company's trivalent hepatitis B (HBV) vaccine met the primary and secondary endpoints. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated January 9, 2020

© Edgar Online, source Glimpses